Prevalence of Weight Related Complications Across Diverse Weight Classifications - A Large Cross-sectional Study in India, Pakistan, Philippines and Vietnam
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 1,170
- Locations
- 25
- Primary Endpoint
- Proportion of Weight-Related Complications Across Different Body Mass Index (BMI) Classes
Study Overview
Brief Summary
This study is investigating how common weight related health problems are in people of different weight categories in India, Pakistan, Philippines, and Vietnam. The purpose of the study is to understand the prevalence of weight related health problems in different weight groups. Participants will continue their normal care and will not get any treatment as part of this study; participants will continue receiving any treatments their doctor has prescribed. The study will last for about 2 years.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Cross Sectional
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Informed consent obtained before any study related activities (study-related activities are any procedure related to recording of data according to the protocol).
- •Male or female aged 18 years or older at the time of signing informed consent.
- •Presence of at least one Weight-related complication.
Exclusion Criteria
- •Participants less than 18 years of age at the time of signing informed consent.
- •Pregnant women and individuals with recent weight loss due to illness, defined as more than 5 percent (%) weight loss in the past 6 months.
Arms & Interventions
Cohort 1
Participants will be assessed for obesity-related complications, including measurement of Body Mass Index (BMI)
Intervention: No treatment given (Other)
Outcomes
Primary Outcomes
Proportion of Weight-Related Complications Across Different Body Mass Index (BMI) Classes
Time Frame: Upon data collection (Day 1)
Percentage (%)
Secondary Outcomes
No secondary outcomes reported